{"id":"NCT01001702","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","briefTitle":"Oral Aripiprazole Open-Label Rollover Study","officialTitle":"An Open- Label Rollover Study for Subjects With Schizophrenia Completing ABILIFY® (Aripiprazole) Clinical Study 31-03-241","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-04","primaryCompletion":"2012-07","completion":"2012-07","firstPosted":"2009-10-27","resultsPosted":"2013-09-27","lastUpdate":"2013-09-27"},"enrollment":85,"design":{"allocation":null,"model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia"],"interventions":[{"type":"DRUG","name":"Aripiprazole","otherNames":["ABILIFY®"]}],"arms":[{"label":"Oral Aripiprazole","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to test the long-term safety and tolerability of oral aripiprazole in adolescent patients with schizophrenia.","primaryOutcome":{"measure":"Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Discontinuation Due to AEs and Deaths","timeFrame":"Up to 72 months","effectByArm":[{"arm":"Oral Aripiprazole","deltaMin":61,"sd":null}],"pValues":[]},"eligibility":{"minAge":"13 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":2},"locations":{"siteCount":15,"countries":["Argentina","Croatia","India","Russia","Serbia","Ukraine"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":85},"commonTop":["Headache","Influenza","Weight increased","Pyrexia","Vomiting"]}}